Fairmount Funds Management LLC - May 29, 2025 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Stock symbol
SYRE
Transactions as of
May 29, 2025
Transactions value $
$0
Form type
4
Date filed
6/2/2025, 04:39 PM
Previous filing
May 1, 2025
Next filing
Jun 3, 2025
SEC
View on sec.gov

Reporting Owners (4)

Name Relationship Address Signature Signature date CIK
Fairmount Funds Management LLC Director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 2025-06-02 0001802528
Harwin Peter Evan Director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak 2025-06-02 0001663607
Kiselak Tomas Director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Peter Harwin 2025-06-02 0001830177
Fairmount Healthcare Fund II L.P. Director 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P. 2025-06-02 0001769651

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +25K $0.00 25K May 29, 2025 Common Stock 25K $15.55 By Peter Harwin F1, F2
transaction SYRE Stock Option (Right to Buy) Award $0 +25K $0.00 25K May 29, 2025 Common Stock 25K $15.55 By Tomas Kiselak F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date.
F2 Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.
F3 This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date.
F4 Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.

Remarks:

The Adviser and Fairmount Healthcare Fund II L.P. may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of the Issuer and are also each a Managing Member of the Adviser.